Phase I clinical and pharmacokinetic trial of the podophyllotoxin derivative NK611 administered as intravenous short infusion

Investigational New Drugs

Volumn 16, Issue 4, 1998, Pages 319-324

  Rassmann I ^a   Thodtmann R ^a,b   Mross, M ^c   Huttmann A ^d   Berdel, W E ^e   Manegold, Ch ^f   Fiebig, H H ^g   Kaeser Frohlich A ^h   Burk, K ^h   Hanauske, A R ^a,b,i  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c UNIVERSITY OF FREIBURG   (Germany)

^d UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^e UNIVERSITY OF MÜNSTER   (Germany)

^f Röntgenabteilung der LVA Baden   (Germany)

^g UNIVERSITY OF FREIBURG   (Germany)

^h ASTA MEDICA AG   (Germany)

ⁱ NONE   (Germany)

Author keywords

Dimethylaminoetoposide; NK611; Pharmacokinetics; Phase I

Indexed keywords

2'' DEOXY 2'' (DIMETHYLAMINO)ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; PODOPHYLLOTOXIN DERIVATIVE;

ADULT; AGED; ALOPECIA; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; COMPARTMENT MODEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG PROTEIN BINDING; DRUG TOLERABILITY; FEMALE; GRANULOCYTOPENIA; HUMAN; INFECTION; INTRAVENOUS DRUG ADMINISTRATION; LIVER CARCINOMA; LUNG NON SMALL CELL CANCER; MALE; NAUSEA; PHASE 1 CLINICAL TRIAL; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; SOLID TUMOR; THROMBOCYTOPENIA;

ADULT; AGED; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; COHORT STUDIES; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; NEOPLASMS; PODOPHYLLOTOXIN;

EID: 6544271428     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006293830585     Document Type: Article

References (11)

1. Machida M, Tanaka S, Nakamori K et al.: Simultaneous determination of NK611, a novel water-soluble derivative of etoposide, and its metabolite (DeNK611) in dogs plasma by column-switching high performance chromatography. Biomedic Chromatograph 7: 82-85, 1993
2. Asta Medica GmbH: Investigator's drug brochure: NK611. Asta Medica GmbH. 1993; p. 35
3. Ekimoto H, Okamoto K, Maruyma S et al.: Preclinical characterization of NK611, a novel water-soluble etoposide analog. Ann Oncol 3 (Suppl 1): 98, 1992
4. Hanauske A-R, Wüster KC, Lehmer A et al.: Activity of NK611, a new epipodophyllotoxin derivative, against colony forming units from freshly explanted human tumors in vitro. Eur J Cancer 31A: 1677-1681, 1995
5. Ekimoto H, Okamoto K, Kusuma K et al.: Treatment schedule dependency of antitumor effects of NK611, a novel watersoluble analog of etoposide, on human xenografts. Proc Amer Assoc Cancer Res 33: 436, 1992
6. Pagani O, Zucchetti M, Sessa C et al.: Phase I clinical and pharmacokinetic study of oral NK611, a new podophyllotoxin derivative. Cancer Chemother Pharmacol 38: 541-547, 1996
7. Rassmann I, Schrödel H, Schilling T et al.: Clinical and pharmacokinetic Phase I trial of oral dimethylaminoetoposide (NK611) administered for 21 days every 35 days. Invest New Drugs 14: 379-386, 1996
8. Schilling T, Mross K, Berdel WE et al.: Phase I clinical and pharmacokinetic trial of the podophyllotoxin derivative NK611. Ann Oncol 5 (Suppl 5): 193, 1994
9. Hüttmann A, Mross K, Hossfeld DK et al.: Determination of the new epidophyllotoxin derivative NK-611 in plasma by high-performance liquid chromatography with ultraviolet detection. J Chromatogr 620: 233-238, 1993
10. Mross K, Hüttmann A, Herbst K et al.: Pharmacokinetics and pharmacodynamics of the new podophyllotoxin derivative NK611. Cancer Chemother Pharmacol 38: 217-224, 1996
11. Stewart CF, Ratain MJ: Topoisomerase interactive agents. In: DeVita VT, Jr, Hellman S et al.: Cancer Principles and Practice of Oncology, 5th Ed., Lippincott-Raven Publ 1997, p 456